The past, present and future of renin-angiotensin aldosterone system inhibition [artículo]
Por: Ruilope Urioste, Luis Miguel [Nefrología]
.
Colaborador(es): Servicio de Nefrología.
Editor: International Journal of Cardiology, 2013Descripción: 167(5):1677-87.Recursos en línea: Solicitar documento Resumen: The renin-angiotensin aldosterone system (RAAS) is central to the pathogenesis of cardiovascular disease. RAAS inhibition can reduce blood pressure, prevent target organ damage in hypertension and diabetes, and improve outcomes in patients with heart failure and/or myocardial infarction. This review presents the history of RAAS inhibition including a summary of key heart failure, myocardial infarction, hypertension and atrial fibrillation trials. Recent developments in RAAS inhibition are discussed including implementation and optimization of current drug therapies. Finally, ongoing clinical trials, opportunities for future trials and issues related to the barriers and approvability of novel RAAS inhibitors are highlighted.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC2136 (Navegar estantería) | Disponible |
Formato Vancouver:
Mentz RJ, Bakris GL, Waeber B, McMurray JJ, Gheorghiade M, Ruilope LM et al. The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol. 2013 Sep 1;167(5):1677-87.
PMID: 23121914
Contiene 129 referencias
The renin-angiotensin aldosterone system (RAAS) is central to the pathogenesis of cardiovascular disease. RAAS inhibition can reduce blood pressure, prevent target organ damage in hypertension and diabetes, and improve outcomes in patients with heart failure and/or myocardial infarction. This review presents the history of RAAS inhibition including a summary of key heart failure, myocardial infarction, hypertension and atrial fibrillation trials. Recent developments in RAAS inhibition are discussed including implementation and optimization of current drug therapies. Finally, ongoing clinical trials, opportunities for future trials and issues related to the barriers and approvability of novel RAAS inhibitors are highlighted.
No hay comentarios para este ejemplar.